Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bile Duct Neoplasms | 3 | 2024 | 124 | 1.510 |
Why?
|
| Cholangiocarcinoma | 3 | 2024 | 123 | 1.510 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 1658 | 0.830 |
Why?
|
| Pancreatic Neoplasms | 5 | 2024 | 729 | 0.810 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 76 | 0.800 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 39 | 0.660 |
Why?
|
| Phenylurea Compounds | 1 | 2020 | 56 | 0.640 |
Why?
|
| Immunoconjugates | 1 | 2020 | 46 | 0.630 |
Why?
|
| Radiosurgery | 1 | 2021 | 147 | 0.620 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 232 | 0.570 |
Why?
|
| Pyrimidines | 1 | 2020 | 418 | 0.520 |
Why?
|
| Patient Selection | 1 | 2020 | 737 | 0.490 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2023 | 169 | 0.480 |
Why?
|
| Proteome | 3 | 2012 | 279 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 1342 | 0.450 |
Why?
|
| Lithostathine | 1 | 2013 | 2 | 0.420 |
Why?
|
| CA-19-9 Antigen | 1 | 2013 | 10 | 0.420 |
Why?
|
| Melanoma | 1 | 2021 | 951 | 0.410 |
Why?
|
| Translocation, Genetic | 2 | 2020 | 356 | 0.390 |
Why?
|
| Pancreatic Juice | 1 | 2011 | 5 | 0.360 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 83 | 0.350 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 1378 | 0.350 |
Why?
|
| Carrier Proteins | 2 | 2013 | 1047 | 0.340 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2008 | 39 | 0.290 |
Why?
|
| Membrane Proteins | 2 | 2013 | 1610 | 0.290 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 356 | 0.280 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2008 | 129 | 0.260 |
Why?
|
| Deoxycytidine | 3 | 2023 | 83 | 0.250 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2024 | 105 | 0.250 |
Why?
|
| Rhabdomyosarcoma | 1 | 2008 | 214 | 0.230 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 697 | 0.230 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2024 | 7 | 0.210 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 126 | 0.200 |
Why?
|
| Mucoproteins | 2 | 2013 | 12 | 0.190 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2022 | 21 | 0.190 |
Why?
|
| Oncogene Proteins | 2 | 2013 | 144 | 0.180 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2021 | 4 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 396 | 0.170 |
Why?
|
| ROC Curve | 2 | 2013 | 601 | 0.170 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1294 | 0.160 |
Why?
|
| Carcinosarcoma | 1 | 2019 | 12 | 0.160 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2019 | 13 | 0.160 |
Why?
|
| Humans | 17 | 2024 | 132061 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 2648 | 0.150 |
Why?
|
| Cisplatin | 1 | 2020 | 281 | 0.150 |
Why?
|
| Neoplasms | 2 | 2012 | 2954 | 0.140 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 270 | 0.140 |
Why?
|
| Mutation | 2 | 2024 | 6229 | 0.140 |
Why?
|
| Rare Diseases | 1 | 2019 | 209 | 0.130 |
Why?
|
| Proteins | 2 | 2013 | 1036 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 1014 | 0.130 |
Why?
|
| Research Design | 1 | 2020 | 741 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 605 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 745 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2024 | 17419 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 3014 | 0.110 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2013 | 10 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 1882 | 0.100 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 3681 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2011 | 2057 | 0.090 |
Why?
|
| Receptors, Polymeric Immunoglobulin | 1 | 2011 | 2 | 0.090 |
Why?
|
| Collagen Type IV | 1 | 2011 | 20 | 0.090 |
Why?
|
| Ascites | 1 | 2011 | 102 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2011 | 95 | 0.080 |
Why?
|
| Pancreas | 1 | 2011 | 222 | 0.080 |
Why?
|
| Limit of Detection | 1 | 2009 | 78 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1353 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1356 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 584 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2008 | 12 | 0.070 |
Why?
|
| PAX3 Transcription Factor | 1 | 2008 | 28 | 0.070 |
Why?
|
| Paired Box Transcription Factors | 1 | 2008 | 75 | 0.070 |
Why?
|
| Biomarkers | 2 | 2023 | 3406 | 0.070 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 137 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 136 | 0.070 |
Why?
|
| Proteomics | 1 | 2011 | 596 | 0.070 |
Why?
|
| Computational Biology | 1 | 2012 | 874 | 0.060 |
Why?
|
| Age Factors | 1 | 2013 | 2912 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2013 | 3418 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 1 | 2008 | 381 | 0.060 |
Why?
|
| Middle Aged | 4 | 2022 | 28964 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 62 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2674 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 244 | 0.050 |
Why?
|
| Brazil | 1 | 2022 | 142 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2021 | 44 | 0.050 |
Why?
|
| Aged | 3 | 2019 | 21406 | 0.050 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2021 | 24 | 0.040 |
Why?
|
| Adult | 3 | 2021 | 31568 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2021 | 114 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 211 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 955 | 0.040 |
Why?
|
| Female | 5 | 2022 | 70712 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 390 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 688 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 299 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 553 | 0.030 |
Why?
|
| Male | 4 | 2021 | 64922 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2021 | 571 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 1131 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 830 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2023 | 13028 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 808 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 2192 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1098 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 945 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5409 | 0.020 |
Why?
|
| Prognosis | 1 | 2019 | 5009 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2012 | 501 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 6567 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 7102 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2021 | 14751 | 0.010 |
Why?
|